Table 1.
NPs | Modification | Analyte | Detection | Performance | Sample | Year | Ref. | |||
---|---|---|---|---|---|---|---|---|---|---|
Tech. | Parameters | Tech. | Parameters | Linear range | LOD | |||||
Ag | DC | 12 μL AgNP-rGO composite, RT | H2O2 | AD | −0.3 V | 0.5 μM to 12 mM | 0.21 μM | Contact lens care solution |
2016 | [26] |
PE | CA, −1.2 V, 10 s | Sulfite | AD | +0.4 V | 1.96 to 16.66 mM | 1.99 mM | Beverages | 2013 | [31] | |
PE |
Step 1: CA, 0.13 V, 5 ms Step 2: CA, 0.24 V, 25 s |
Metronidazole | DPV | Eamp: −0.1 V 0.075 Vs−1 |
3.1 to 310 μM | 0.4 μM | Serum, Urine, and Tablets |
2012 | [32] | |
PE | CA, −1.2 V, 120 s | Lamotrigine | DPCSV (CA+DPV) |
A: −0.90, 147 s | 0.33 to 1.50 μM | 0.372 μM | Pharmaceuticals | 2007 | [33] | |
PE | CA, −1.2 V, 20 s | Chloride Bromide Iodide |
LSV | −0.2 to 0.6 V, 0.01 V s−1 | 3 μM to 100 μM 5 μM to 90 μM 5 μM to 80 μM |
3 μM 5 μM 5 μM |
Synthetic sweat | 2018 | [34] | |
Au | IM | Ionophore based ink | Trazodone | OCP | - | 10 μM to 10 mM | 6.8 μM | Pharmaceuticals | 2018 | [15] |
DC | - | Carbofuran | DPCSV (CA+DPV) |
A: 0 V, 60 s DPV: −0.2 to 0.35 V, Ep: 0.15 V, tp: 0.3 s, Estep: 0.01 V |
1–250 µM | 0.22 µM | Food | 2017 | [21] | |
DC | 1.8 µL AuNPs Graphene composite, RT, 12 h |
H2O2 Glucose |
AD | −0.2V | 0.2 to 4.2 mM 2 to 10mM |
− 180 µM |
Blood | 2010 | [28] | |
PE | CA, +0.18 V, 10 s | Sulfite | AD | +0.3 V | 9.8 to 83.33 μM | 9.79 μM | Beverages | 2013 | [31] | |
PE | CA, +0.18 V, 50 s | Ascorbic acid | DPV | −0.2 to 0.8 V, 0.1 V s−1 Ep: 0.012 V, tp: 0.07 s, Estep: 0.025 V |
1.9 to 16.6 μM | 0.99 μM | Serum | 2017 | [35] | |
HEA-GE |
Step 1: CP, 3 Acm−2, 100 s, RT Step 2: CV, 10 cycles, −0.7 to 0.4 V, 0.05 Vs−1 |
Glucose | AD | −0.2 V | 1.5 and 16 mM | 25 µM | Serum | 2018 | [36] | |
PE | CA, −0.2 V, 150 s | Glycated hemoglobin |
CV | 0 to −0.6 V, 0.1 Vs−1 Calibrated at −0.45 V |
2 to 20% | 0.65% | Serum | 2019 | [58] | |
PE | CV, 5 cycles +0.4 to −0.6 V, 0.05 Vs−1 |
Sulfide | DPCSV (CA+DPV) |
A, +0.4 V, 60 s DPV: +0.4 to −0.9 V, Ep: 0.008 V, tp: 0.05 s, Estep: 0.1 V |
0.05 to 1.5 μM | 0,2 uM | Tap water | 2016 | [59] | |
GE | CP, −100 μA, 6000 s | Glucose | CV | −0.3 to +0.5 V, 0.1 Vs−1 | 0.01 to 5 mM | 6 µM | Beverages | 2017 | [64] | |
Bi | PE | CA, −1 V, 4 min | Phenol | CA | +0.8 V, 150 s | 5 to 100 µM | 480 nM | Wastewater | 2010 | [38] |
PE | CV, 20 cycles −0.6 to 0.3 V |
H2O2 | CV | −0.3 to −1.3 V | 100 µM to 5 mM | 57 µM | Cosmetic | 2011 | [39] | |
SD | 1.2 kV, 20 cycles | Riboflavin | SWV | 0 to −0.8 V, Freq: 50 Hz, Eamp: 0.05 V, Estep: 0.0015 V |
1 to 100 nM | 0.7 nM | Multivitamin | 2015 | [67] | |
Cu | GE | CP, −225 μA, 60 s | Glucose Fructose Arabinose Galactose Mannose Xylose |
CA | +0.65 V, 100 s | 1 μM to 10 mΜ | 0.57 μM 0.61 μM 1.0 μM 0.89 μM 1.3 μM 1.04 μM |
Honey and beverages |
2017 | [42] |
IM | Ink with 50% of Cu(OH)2 nanorods |
Ascorbic acid | CA | 0 V, 25 s | 0.0125 to 10 mΜ | 6 mM | Tablets Urine |
2017 | [89] | |
Ir | IM | Ink with 0,9:5 of Ir-C powder (5 % Ir) |
Triglyceride | CA | +0.15 V, 30 s | Up to 10 mM | - | Serum | 2008 | [11] |
Ni | DC | 15 μL (10 g L−1) Activation: A, −1.5 V, 600 s in NaOH 0.1 M |
Glucose Fructose Mix 1:1 |
AD, FIA | +0.7 V, 2 mL min−1 | 0.05 to 1 mM | 0.06 mM 0.04 mM 0.04 mM |
Honey | 2012 | [24] |
HEA-GE | CP, 0.1 A, 30 s | Glucose | CA | +0.5 V, 100 s | 0.5 μM to 4 mM | 0.07 μM | Blood | 2013 | [45] | |
PE | CV, 40 cycles, 0.05 Vs−1, 0 to −1.5 V Activation: CV, 40 cycles, 0.1 Vs−1, 0 to +0.8 V in 0.1 M NaOH |
Glucose | AD | +0.6 V | 0.2 to 9 mM | 4.1 μM | Urine | 2013 | [46] | |
GE | CP, −25 μA, 60 s Activation: CV, 50 cycles, 0.1 Vs−1, +0.2 to +0.7 V in 0.1 M NaOH |
Glucose Fructose |
CA | +0.6 V, 120 s | 25 to 1000 μM | Between 8 μM and 20 μM |
Food | 2016 | [47] | |
Pd | PE | CV, 10 cycles, 0.05 Vs−1 −0.25 to +1.2 V |
Dopamine | DPV | −0.1 to +0.6 V | 0.35 to 135.35 µM | 0.056 µM | Injection | 2015 | [48] |
PE | CV, 20 cycles, 0.02 Vs−1 +1.2 to −0.25 V |
Hydrazine | AD | −0.05 V | 0.05 to 1415 µM | 4 nM | Drainage water | 2016 | [49] | |
PE | CA, −0.6 V, 180 s | Dissolved O2 | CV | 0.5 to −0.3 V, 0.02 V s−1 | Up to 250 µM | - | Ground and tap water |
2006 | [50] | |
Pt | DC | 12 μL, RT, 24 h | H2O2 | AD | −0.3 V | 1 µM to 10 mM | 0.43 µM | Contact lens care solution |
2016 | [17] |
DC | 20 μL, dried at 80 ˚C, 10 min | H2O2 | AD | 0.345 V | Up to 0.1 mM | 6.6 µM | Whitening Strips | 2015 | [18] | |
DC | 10 μL (2 g L−1), dried at 40 ˚C, 180 min |
Ethanol | LSV | −1 to 1 V, 0.05 V s−1 | 15 to 102 mM | 15 mM | Beverages | 2017 | [19] | |
DC | 0.5 µL PtNP-MWCNT composite, RT |
H2O2 | CA | +0.3 V, 60 s | 10 to 100 µM | 10 µM | Green tea | 2018 | [25] | |
PE | CA, −0.5 V, 300 s | H2O2 | CA | −0.7 V, 30 s | 500 µM to 20 mM | 32.8 µM | Serum | 2017 | [51] | |
PE | CA, −0.4 V, 900 s | H2O2 | AD | +0.7 V | 6 to 215 µM | 7.6 µM | Hair lightener Antiseptic Plant extract |
2017 | [53] | |
PE | CA, 12.4 V, 12 min | H2O2 | AD | +0.7 V | Up to 6.5 mM | 80 µM | Hair lightener | 2018 | [56] | |
Rh | DC | 15 μL, RT | H2O2 | AD | 0 V | 5 to 600 μM | 2 μM | Tea extracts | 2015 | [20] |
PE | CA, −0.25 V, 480 s | Bromide | CSV (CA+LSV) |
A: +1.25 V, 20 s LSV: +1 to −0.25 |
Up to 40 mM | 39 μM | Seawater Pharmaceuticals |
2019 | [57] |
AD: Amperometric detection; CA: Chronoamperometry; CP: Chronopotentiommetry; CV: Cyclic Voltammetry; CSV: Cathodic Stripping Voltammetry; DC: Drop-Casting; DPCSV: Differential-Pulse Cathodic Stripping Voltammetry; DPV: Differential Pulse Voltammetry; FIA: Flow Injection Analysis; GE: Galvanostatic electrodeposition; HEA-GE: Hydrogen-Evolution-Assisted Galvanostatic Electrodeposition; IM: Ink-Mixing; LSV: Linear Sweep Voltammetry; OCP: Open Circuit Potential; PE: Potentiostatic electrodeposition; RT: Room Temperature; SD: Spark Discharge; SWV: Square Wave Voltammetry; Tech.: electrochemical technique.